Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protozoal cysteine proteases are a major class of enzymes employed by parasites to facilitate infection, tissue invasion, immune evasion, protein degradation, autophagy, and cellular egress[1][2]. The most well-characterized families include clan CA cysteine proteases—particularly family C1 cathepsin-like enzymes—which are considered druggable targets in malaria (*Plasmodium* falcipain), Chagas disease (*Trypanosoma cruzi* cruzipain), leishmaniasis, and other protozoan infections. These proteases commonly hydrolyze host or parasite proteins and are involved in key biological processes, including hemoglobin degradation (in *Plasmodium*), cell penetration, and autophagy. Inhibiting these enzymes is a promising approach for chemotherapeutic and vaccine strategies. However, the term "protozoal cysteine-containing proteins" is not standard; the precise therapeutic target class is "protozoal cysteine protease"[1][2].
Inhibition of proteolytic (protein-degrading) activity by covalent or non-covalent blockade of the catalytic cysteine residue
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protozoal cysteine protease.